Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study.
Jie HuangShujuan SunQiaorui TanFangchao ZhengDongdong ZhouXiaochu ManYu HuWenhuan LiLihua SongBaoxuan ZhangLiang XuXinzhao WangXuemei XieHuihui LiPublished in: Clinical breast cancer (2024)
Pyrotinib-based therapy is effective and tolerable in human epidermal growth factor receptor 2-positive metastatic breast cancer with BMs. Patients who underwent radiotherapy for BMs, particularly those who received pyrotinib concurrently with radiotherapy, exhibited a more favorable prognosis.
Keyphrases
- epidermal growth factor receptor
- positive breast cancer
- metastatic breast cancer
- brain metastases
- end stage renal disease
- early stage
- small cell lung cancer
- tyrosine kinase
- ejection fraction
- endothelial cells
- radiation therapy
- newly diagnosed
- chronic kidney disease
- locally advanced
- advanced non small cell lung cancer
- prognostic factors
- radiation induced
- stem cells
- peritoneal dialysis
- squamous cell carcinoma
- patient reported outcomes
- cross sectional
- combination therapy
- rectal cancer